Johnson Matthey PLC (LON:JMAT - Get Free Report) insider Liam Condon purchased 12 shares of the company's stock in a transaction that occurred on Friday, October 10th. The shares were purchased at an average cost of GBX 2,079 per share, for a total transaction of £249.48.
Liam Condon also recently made the following trade(s):
- On Tuesday, August 12th, Liam Condon acquired 14 shares of Johnson Matthey stock. The stock was bought at an average cost of GBX 1,773 per share, with a total value of £248.22.
Johnson Matthey Stock Up 1.6%
Shares of Johnson Matthey stock traded up GBX 34 on Monday, hitting GBX 2,100. The company had a trading volume of 582,793 shares, compared to its average volume of 1,798,039. The stock has a market capitalization of £3.52 billion, a price-to-earnings ratio of 994.32, a P/E/G ratio of 49,242.50 and a beta of 0.95. Johnson Matthey PLC has a 1 year low of GBX 1,131 and a 1 year high of GBX 2,112. The stock has a 50 day moving average of GBX 1,912.66 and a 200-day moving average of GBX 1,678. The company has a debt-to-equity ratio of 62.73, a quick ratio of 0.76 and a current ratio of 1.45.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on JMAT shares. Deutsche Bank Aktiengesellschaft increased their price objective on Johnson Matthey from GBX 2,100 to GBX 2,300 and gave the stock a "buy" rating in a research note on Thursday. Berenberg Bank increased their price target on Johnson Matthey from GBX 1,950 to GBX 2,100 and gave the company a "hold" rating in a research report on Thursday. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of GBX 2,066.67.
View Our Latest Analysis on Johnson Matthey
About Johnson Matthey
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers' products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet's natural resources.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.